Mark T. Iwicki, Director at Aimmune Therapeutics, Inc. (AIMT), bought 9,375 shares at $32.00 ($300K) on 2018-02-26, disclosed to the SEC on 2018-02-26.
Open-market purchase of $300k AIMT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| KALA | SELL | 2025-06-05 | $41K | — | Filing → |
| KALA | SELL | 2025-01-07 | $44K | — | Filing → |
| KALA | SELL | 2024-06-27 | $72K | — | Filing → |